1-3 of 3
Prabir Chakraborty, PhD
Close
Sort by
Journal Articles

AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics

William Casey Wilson, PhD, John Richards, PhD, Robyn J Puro, PhD, Gabriela Andrejeva, PhD, Ben J Capoccia, PhD, Mike J Donio, Ronald R Hiebsch, BS, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-139655
Published: 2020
Journal Articles

Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination

John Richards, PhD, Myriam N Bouchlaka, BS,PhD, Robyn J Puro, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, W. Casey Wilson, PhD, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1844.
https://doi.org/10.1182/blood-2019-126298
Published: 2019
Journal Articles

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

W. Casey Wilson, PhD, Myriam N Bouchlaka, BS, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, Robyn J Puro, PhD, Alun J Carter, PhD, Prabir Chakraborty, PhD, Pamela T Manning, PhD, Robert W Karr, MD, Vicki Sung, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4180.
https://doi.org/10.1182/blood-2018-99-118456
Published: 2018